Eli Lilly, the makers of tirzepatide—which they sell as Mounjaro for diabetes and Zepbound for weight loss— announced recently that in its longest study yet on tirzepatide, the drug reduced the risk of people with prediabetes moving on to develop diabetes by 94% compared to those taking a placebo.

Novo Nordisk's weight loss drug, Saxenda, helped children ages six to 11 reduce their body mass index in a recent trial.

Children aged between six and 12 saw their BMI fall by 7.4 per cent in a trial which researchers say could offer 'considerable promise to children living with obesity'

Blockbuster weight loss drugs have been arguably the biggest health story of the last several years — and there are no signs their popularity will slow down anytime soon. Millions of Americans have taken the drugs,

Ozempic and other weight-loss injections have recently been revolutionising the treatment of obesity. But this transformation may be nothing compared to the impact of the next generation of weight-loss drugs, which will be available in tablet form, with early results suggesting it will be even more potent.